Study characteristics for diagnosing type 2 VWD using VWF:RCo/antigen ratio
| Study . | Study design . | Total patients (type 2M VWD), n . | Reference standard . | Prevalence, % . |
|---|---|---|---|---|
| Vangenechten et al, 201834 | Cross-sectional, case control | 142 (8) | PFA, RIPA, VWF:Ag, FVIII:C, VWF:CB, molecular diagnosis through DNA sequencing | 37 |
| de Maistre et al, 201433 | Cross-sectional, case control | 80 (16) | Molecular analysis was performed to confirm the classification. | 58 |
| Chen et al, 201132 | Cross-sectional, case control | 453 (4) | Based on results of VWF:Ag, VWF:RCo, and VWF multimer analysis and available clinical information, samples were categorized as normal; VWD types 1, 2A/B, 2M, or severe 1 vs 2M; or AVWA as a result of the subtle loss of highest molecular weight multimers. | 6 |
| James et al, 200731 | Cross-sectional, case control | 16 (all) | A blood sample was obtained from all of the index cases, and genomic DNA was isolated from leukocytes using a salt-extraction method. | N/A |
| Caron et al, 200630 | Cross-sectional, case control | 31 (0) | RIPA and genetic testing | N/A |
| Adcock et al, 200629 | Cross-sectional, cohort | 497 (1) | VWF multimeric analysis, VWF:Ag, ristocetin cofactor activity, and collagen-binding activity | 10 |
| Study . | Study design . | Total patients (type 2M VWD), n . | Reference standard . | Prevalence, % . |
|---|---|---|---|---|
| Vangenechten et al, 201834 | Cross-sectional, case control | 142 (8) | PFA, RIPA, VWF:Ag, FVIII:C, VWF:CB, molecular diagnosis through DNA sequencing | 37 |
| de Maistre et al, 201433 | Cross-sectional, case control | 80 (16) | Molecular analysis was performed to confirm the classification. | 58 |
| Chen et al, 201132 | Cross-sectional, case control | 453 (4) | Based on results of VWF:Ag, VWF:RCo, and VWF multimer analysis and available clinical information, samples were categorized as normal; VWD types 1, 2A/B, 2M, or severe 1 vs 2M; or AVWA as a result of the subtle loss of highest molecular weight multimers. | 6 |
| James et al, 200731 | Cross-sectional, case control | 16 (all) | A blood sample was obtained from all of the index cases, and genomic DNA was isolated from leukocytes using a salt-extraction method. | N/A |
| Caron et al, 200630 | Cross-sectional, case control | 31 (0) | RIPA and genetic testing | N/A |
| Adcock et al, 200629 | Cross-sectional, cohort | 497 (1) | VWF multimeric analysis, VWF:Ag, ristocetin cofactor activity, and collagen-binding activity | 10 |
AVWA, acquired VWF abnormalities; FVIII:C, FVIII activity; FVIII:CB, FVIII collagen binding; N/A, Not available; PFA, platelet function analyzer; RIPA, ristocetin-induced platelet aggregation.